

Gj Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10892993/publications.pdf>

Version: 2024-02-01

101
papers

4,284
citations

101543

36
h-index

133252

59
g-index

101
all docs

101
docs citations

101
times ranked

4453
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2002, 38, 349-358.	2.8	313
2	Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2002, 1587, 194-205.	3.8	304
3	Basis for effective combination cancer chemotherapy with antimetabolites. , 2000, 87, 227-253.		247
4	5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. <i>Annals of Oncology</i> , 2004, 15, 1025-1032.	1.2	196
5	Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. <i>Annals of Oncology</i> , 2000, 11, 385-391.	1.2	143
6	Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. <i>European Journal of Cancer</i> , 1999, 35, 796-807.	2.8	132
7	Comparison of 5-fluoro-2-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. <i>European Journal of Cancer</i> , 1998, 34, 296-306.	2.8	95
8	Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. <i>European Journal of Cancer</i> , 2000, 36, 916-924.	2.8	87
9	mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. <i>Leukemia</i> , 2000, 14, 2166-2175.	7.2	84
10	Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. <i>Annals of Oncology</i> , 1999, 10, 441-448.	1.2	81
11	Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice. <i>European Journal of Cancer</i> , 1999, 35, 808-814.	2.8	69
12	Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). <i>Investigational New Drugs</i> , 1987, 5, 235-44.	2.6	66
13	Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. <i>European Journal of Cancer</i> , 1995, 31, 2335-2340.	2.8	64
14	Gemcitabine+cisplatin: A schedule finding study. <i>Annals of Oncology</i> , 1999, 10, 1503-1510.	1.2	64
15	Clinical and Pharmacologic Study of Orally Administrated Uridine. <i>Journal of the National Cancer Institute</i> , 1991, 83, 437-442.	6.3	62
16	In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. <i>British Journal of Cancer</i> , 1988, 57, 259-265.	6.4	61
17	DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. <i>British Journal of Cancer</i> , 1995, 72, 917-921.	6.4	60
18	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. <i>Annals of Oncology</i> , 2009, 20, 182-187.	1.2	60

#	ARTICLE	IF	CITATIONS
19	Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. <i>International Journal of Cancer</i> , 2000, 87, 771-778.	5.1	59
20	5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. <i>Annals of Oncology</i> , 2001, 12, 209-216.	1.2	59
21	Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. <i>European Journal of Cancer</i> , 2005, 41, 1150-1157.	2.8	53
22	Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. <i>Annals of Oncology</i> , 2001, 12, 779-785.	1.2	51
23	Purine and pyrimidine metabolism in peripheral blood lymphocytes. <i>International Journal of Biochemistry & Cell Biology</i> , 1983, 15, 115-123.	0.5	50
24	Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. <i>European Journal of Cancer</i> , 2003, 39, 1310-1317.	2.8	50
25	Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2004, 15, 831-838.	1.2	48
26	Reversal of 5-Fluorouracil-Induced Myelosuppression by Prolonged Administration of High-Dose Uridine. <i>Journal of the National Cancer Institute</i> , 1989, 81, 157-162.	6.3	46
27	Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. <i>Annals of Oncology</i> , 2006, 17, 35-42.	1.2	46
28	The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 812-819.	1.3	44
29	Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. <i>European Journal of Cancer</i> , 2003, 39, 691-697.	2.8	43
30	Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. <i>Annals of Oncology</i> , 2005, 16, 1646-1653.	1.2	43
31	Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1983, 759, 7-15.	2.4	42
32	The determination of gemcitabine and 2â€²-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 847, 142-152.	2.3	42
33	Differences in the Induction of DNA Damage, Cell Cycle Arrest, and Cell Death by 5-Fluorouracil and Antifolates. <i>Oncology Research</i> , 2001, 12, 231-239.	1.5	41
34	DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. <i>Annals of Oncology</i> , 2009, 20, 1048-1056.	1.2	41
35	Cross-resistance in the 2â€²,2â€²-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. <i>European Journal of Cancer</i> , 2000, 36, 1974-1983.	2.8	40
36	Enhanced therapeutic efficacy of 5'-deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. <i>British Journal of Cancer</i> , 1989, 59, 327-334.	6.4	39

#	ARTICLE	IF	CITATIONS
37	In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine. <i>British Journal of Cancer</i> , 1992, 65, 229-233.	6.4	38
38	Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. <i>Leukemia Research</i> , 1992, 16, 873-880.	0.8	38
39	Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry. <i>Biomedical Applications</i> , 1985, 343, 59-66.	1.7	37
40	Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule. <i>Journal of Chemotherapy</i> , 2007, 19, 212-221.	1.5	36
41	Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. <i>General Pharmacology</i> , 1996, 27, 421-429.	0.7	34
42	Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. <i>BJU International</i> , 2004, 93, 491-494.	2.5	34
43	Postconfluent multilayered cell line cultures for selective screening of gemcitabine. <i>European Journal of Cancer</i> , 1998, 34, 921-926.	2.8	33
44	Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high-performance liquid chromatography on a column with porous polymeric packing. <i>Biomedical Applications</i> , 1984, 307, 464-468.	1.7	32
45	DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effects. <i>Biochemical Pharmacology</i> , 1988, 37, 3257-3266.	4.4	32
46	Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. <i>Biochemical Pharmacology</i> , 2010, 80, 786-792.	4.4	31
47	Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 22, 785-789.	0.8	30
48	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2004, 15, 230-235.	1.2	30
49	Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. <i>European Journal of Cancer</i> , 1997, 33, 471-478.	2.8	29
50	Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. <i>European Journal of Cancer</i> , 2000, 36, 2420-2429.	2.8	29
51	Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells. <i>Bioorganic Chemistry</i> , 2016, 64, 51-58.	4.1	28
52	Adenosine and deoxyadenosine metabolism in mammalian lymphocytes. <i>International Journal of Biochemistry & Cell Biology</i> , 1981, 13, 445-455.	0.5	27
53	Retention of in vivo antipyrimidine effects of brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. <i>Biochemical Pharmacology</i> , 1990, 39, 135-144.	4.4	26
54	Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. <i>Annals of Oncology</i> , 1993, 4, 317-320.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. <i>European Journal of Cancer</i> , 1994, 30, 1408-1411.	2.8	26
56	Concentration, synthesis and utilization of phosphoribosylpyrophosphate in lymphocytes of five mammalian species. <i>International Journal of Biochemistry & Cell Biology</i> , 1979, 10, 885-888.	0.5	25
57	Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. <i>British Journal of Cancer</i> , 1992, 66, 660-665.	6.4	25
58	Separation of several 5-Fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-Fluorouracil-nucleotide sugars. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 1425-1431.	0.7	24
59	Quantification of 5-Fluorouracil Incorporation into RNA of Human and Murine Tumors as Measured with a Sensitive Gas Chromatography-Mass Spectrometry Assay. <i>Analytical Biochemistry</i> , 1995, 231, 157-163.	2.4	24
60	A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 1987, 161, 32-38.	2.4	23
61	Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 516-523.	0.7	23
62	Determination of the Antimetabolite Gemcitabine (2',2'-Difluoro-2'-deoxycytidine) and of 2',2'-Difluoro-2'-deoxyuridine by ¹⁹ F Nuclear Magnetic Resonance Spectroscopy. <i>Analytical Biochemistry</i> , 1993, 214, 25-30.	2.4	23
63	Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 675-679.	2.1	23
64	The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. <i>Biochemical Pharmacology</i> , 2007, 73, 1548-1557.	4.4	23
65	Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. <i>Cancer Science</i> , 2008, 99, 2302-2308.	3.9	23
66	Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 217-224.	4.0	20
67	Expression of 5'-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage. <i>Blood</i> , 1991, 78, 488-492.	1.4	19
68	Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. <i>European Journal of Cancer</i> , 1995, 31, 1517-1525.	2.8	19
69	Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. <i>British Journal of Pharmacology</i> , 2011, 163, 722-731.	5.4	19
70	Towards Tailored Therapy of Glioblastoma Multiforme. <i>Journal of Chemotherapy</i> , 2011, 23, 187-199.	1.5	19
71	Metabolism of phosphoribosylpyrophosphate in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. <i>International Journal of Biochemistry & Cell Biology</i> , 1981, 13, 577-583.	0.5	18
72	A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. <i>European Journal of Cancer</i> , 2001, 37, 492-498.	2.8	18

#	ARTICLE	IF	CITATIONS
73	Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2004, 15, 484-488.	1.2	18
74	A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. <i>European Journal of Cancer</i> , 2009, 45, 2519-2527.	2.8	18
75	Pyrimidine metabolism in lymphocytes and erythrocytes of man, horse and cattle. <i>International Journal of Biochemistry & Cell Biology</i> , 1979, 10, 7-10.	0.5	17
76	The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. <i>International Journal of Biochemistry & Cell Biology</i> , 1985, 17, 95-99.	0.5	17
77	Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: Relationship between plasma concentrations and clinical parameters. <i>European Journal of Cancer</i> , 1995, 31, 1465-1470.	2.8	15
78	Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach. <i>Journal of Chemotherapy</i> , 2004, 16, 25-30.	1.5	15
79	Effects of adenosine and deoxyadenosine on pha-stimulation of lymphocytes of man, horse and pig. <i>International Journal of Biochemistry & Cell Biology</i> , 1982, 14, 377-385.	0.5	14
80	The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 1759-1765.	2.8	14
81	Chemosensitizing acridones: In vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies. <i>Journal of Molecular Graphics and Modelling</i> , 2013, 40, 116-124.	2.4	13
82	Stimulation by phytohaemagglutinin of peripheral blood lymphocytes from horse, pig, sheep and man. <i>Veterinary Immunology and Immunopathology</i> , 1982, 3, 295-300.	1.2	12
83	Augmentation of 1- β -d-Arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisingalling drugs. <i>European Journal of Cancer</i> , 1998, 34, 895-901.	2.8	12
84	Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Pigs. <i>European Urology</i> , 2003, 44, 615-619.	1.9	12
85	Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts. <i>Cancer Letters</i> , 1990, 49, 133-137.	7.2	11
86	A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114527.	5.5	11
87	Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. <i>Leukemia</i> , 2002, 16, 949-951.	7.2	10
88	Pharmacokinetics of Bolus 5-Fluorouracil: Relationship Between Dose, Plasma Concentrations, Area-Under-the-Curve and Toxicity. <i>Journal of Chemotherapy</i> , 2005, 17, 315-320.	1.5	10
89	Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs. <i>Trends in Food Science and Technology</i> , 2005, 16, 289-297.	15.1	10
90	Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines. <i>Journal of Chemotherapy</i> , 2009, 21, 338-346.	1.5	10

#	ARTICLE	IF	CITATIONS
91	In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. <i>British Journal of Cancer</i> , 1993, 68, 702-707.	6.4	9
92	Pyrimidine metabolism in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. <i>International Journal of Biochemistry & Cell Biology</i> , 1983, 15, 51-55.	0.5	7
93	Metabolism of purine nucleosides in human and ovine lymphocytes and rat thymocytes and their influence on mitogenic stimulation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1983, 755, 127-136.	2.4	7
94	Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. <i>FEBS Letters</i> , 1984, 170, 277-280.	2.8	6
95	Discrepancies in ribonucleotide concentrations in human lymphocytes isolated from heparinized and defibrinized blood. <i>Clinica Chimica Acta</i> , 1985, 145, 349-355.	1.1	6
96	Novel approaches to selective treatments of human solid tumors: Laboratory and clinical correlation. <i>Annals of Oncology</i> , 1993, 4, 277-281.	1.2	6
97	The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by Brequinar Sodium. <i>Cancer Letters</i> , 1989, 46, 123-127.	7.2	5
98	Thymidine phosphorylase as a target for antiangiogenesis treatment. <i>Nucleic Acids Symposium Series</i> , 2008, 52, 629-629.	0.3	5
99	Metabolism of purine nucleosides and phosphoribosylpyrophosphate in thymocytes and splenocytes of various mammalian species. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1982, 73, 535-541.	0.2	2
100	Precision medicine in cancer: beyond wishful thinking?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 1-3.	0.7	2
101	EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 128-140.	2.2	1